- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02825537
Study of the Effect of Elastic Compression (French Class III) on Water Balance Change in Healthy Subjects
August 23, 2016 updated by: Laboratoires Innothera
Study of the Effect of Class III Elastic Venous Compression Focused on 33 mmHg on Water Balance Change in Healthy Subjects. Exploratory, Randomized, Open-label, Controlled and Crossover Study
The main objective of this study is to compare precisely, under standardized test conditions, water balance changes in healthy subjects with or without the daytime use of compression stocking.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rennes, France, 35042
- Biotrial
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male subject aged 40 years old or more,
- Subject with a Body Mass Index (BMI) between 18.5 and 30 kg/m²,
- Subject with a body fat percentage between 11 and 27 % of his weight, as measured by impedancemetry,
- Subject with a muscle mass index of less than 55% of his weight, as measured by impedancemetry,
- Subject with a water status, as measured by impedancemetry, between + / - 5 liters of his normal value, as indicated by the impedancemetry,
- Healthy subject, registered in the French biomedical research volunteer national database,
- Subject whose lower limb measurements correspond to the size grid of the compression stocking used,
- Subject agreeing to abstain from alcohol intake during all hospitalization periods,
- Subject practicing under 5 hours of intense physical activity per week, on average, in the 4 weeks preceding the screening visit (marathon training, military training ...),
- Subject agreeing to abstain from any strenuous activity , especially sports, from the screening visit to the end of study (including during the out-patient period),
- Subject accepting the constraints of the study,
- Subject being available during the whole period of the study,
- Subject who has signed the consent form after being adequately informed and receiving the information sheet,
- Subject affiliated to the French social security system or receiving benefits of that type.
Exclusion criteria:
- Subject who is a smoker or a former smoker who stopped smoking less than 6 months ago,
- Subject following a salt-free diet,
- Subject following or planning to follow a diet,
- Subject having a temperature ≥ 38,5°C in the morning,
- Subject having, upon clinical examination, a systolic blood pressure (SBP) < 91 mmHg or > 139 mmHg, a diastolic blood pressure (DBP) < 41 mmHg or > 89 mmHg, or a heart rate (HR) < 40 bpm or > 100 bpm, and judged clinically significant by the investigator,
- Subject having an intestinal transit disorder that disrupts hydroelectric balance,
- Alcohol-dependent subject or subject with a positive alcohol breath test,
- Subject having a localized or general edema (a simple evening edema of the legs or ankles is accepted for inclusion),
- Subject suffering from insulin-dependent or uncontrolled diabetes (controlled diabetes is accepted),
- Subject with a serious, stabilized, or progressive illness (as judged by the investigator),
- Subject with hypertension or heart failure,
- Subject with known renal function disorders,
- Subject with known liver failure,
- Subject with venous insufficiency of clinical class C3, C4, C5 or C6 according to the Clinical / Etiological / Anatomical / Pathophysiological (CEAP) classification,
- Subject following long-term therapy with diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, nutritional supplements or opiates,
- Subject having, upon questioning or clinical examination, advanced peripheral neuropathy, skin infections, eczematous dermatitis, or weeping skin disorder of the leg,
- Subject with a medical contraindication to compression therapy according to the interview or clinical examination: phlegmatia coerulea dolens, septic thrombosis, intolerance to the product including the self-supporting band, allergic reaction to any component, arteritis obliterans of lower limbs, advanced diabetic microangiopathy,
- Subject with active implants, such as a pacemaker or other mechanical heart device , and non-active implants, for example a hip prosthesis (dental implants are authorized),
- Subject who is participating in another clinical trial or who is in the exclusion period from a previous study,
- Person deprived of freedom by judicial or administrative decision, or a person hospitalized without their consent,
- Subject of legal age who is protected by law or under guardianship,
- Subject with a current mental or psychiatric disorder or a history of mental or psychiatric disorder, or any other factor limiting the collection of informed consent,
- Person who works for the Contract Research Organisation or for Innothéra laboratories, or has a dependent relationship with these entities.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: With use of compression stocking
Use of compression stocking during 3 consecutives days
|
A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
|
|
Other: Without use of compression stocking
No use of compression stocking during 3 consecutives days
|
No use of compression stocking
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evolution of the total bodily fluid volume in the daytime sequence measured by impedancemetry with or without daytime use of compression stocking
Time Frame: adjusted over 3 consecutive days
|
adjusted over 3 consecutive days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evolution of the water balance in daytime sequence,in night sequence and on a 24h sequence with or without daytime use of compression stocking
Time Frame: adjusted over 3 consecutive days
|
adjusted over 3 consecutive days
|
|
Evolution of the subject's weight (in kilograms), in daytime sequence, in night sequence and on a 24 h sequence with or without daytime use of compression stocking
Time Frame: adjusted over 3 consecutive days
|
adjusted over 3 consecutive days
|
|
Evolution of the volume of urine determined by weight (in kilograms),in daytime sequence, in night sequence and a 24h sequence with or without daytime use of compression stocking
Time Frame: adjusted over 3 consecutive days
|
adjusted over 3 consecutive days
|
|
Evolution days of the neck circumference (in centimeter) in a dynamic sequence, in supine sequence and on a 24h sequence with or without daytime use of compression stocking
Time Frame: adjusted over 3 consecutive days
|
adjusted over 3 consecutive days
|
|
Evolution of leg perimeters (in centimeter) in 3 points in dynamic sequence, in supine sequence , and over 24h sequence with or without daytime use of compression stocking
Time Frame: adjusted over 3 consecutive days
|
adjusted over 3 consecutive days
|
|
Evolution of the time and volume of the first urine after H0 determined by weight (in kilograms) with or without daytime use of compression stocking
Time Frame: adjusted over 3 consecutive days
|
adjusted over 3 consecutive days
|
|
Evolution of the quantity of NaCl excreted in urine in daytime sequence, in night sequence, and over 24 h sequence with or without daytime use of compression stocking
Time Frame: adjusted over 3 consecutive days
|
adjusted over 3 consecutive days
|
|
Evolution of the total bodily fluid volume in night sequence and on a 24h sequence measured by impedancemetry with or without daytime use of compression stocking
Time Frame: adjusted over 3 consecutive days
|
adjusted over 3 consecutive days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Hakim Charfi, MD, Biotrial
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2016
Primary Completion (Actual)
August 1, 2016
Study Completion (Actual)
August 1, 2016
Study Registration Dates
First Submitted
June 30, 2016
First Submitted That Met QC Criteria
July 4, 2016
First Posted (Estimate)
July 7, 2016
Study Record Updates
Last Update Posted (Estimate)
August 24, 2016
Last Update Submitted That Met QC Criteria
August 23, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- CVE101-15
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
PfizerCompletedHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
Vichy LaboratoiresCentre de Pharmacologie Clinique Applique a la DermatologieCompletedHealthy Subjects | Healthy AdultFrance
-
Yuhan CorporationCompletedAtopic Healthy Subjects | Adult Subjects With Allergic DiseasesKorea, Republic of
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Not yet recruitingHealthy Subjects
-
ZabBio Inc.Boston University; Eunice Kennedy Shriver National Institute of Child Health... and other collaboratorsRecruiting
-
NovoBliss Research Pvt LtdOneSto Labs Private Ltd.Not yet recruiting
Clinical Trials on Compression stocking
-
University Hospitals Cleveland Medical CenterWithdrawn
-
Imperial College LondonUniversity College, London; University of Edinburgh; University of Manchester; Universidad...TerminatedDeep Vein Thrombosis | Post Thrombotic Syndrome | Deep Vein Thrombosis LegUnited Kingdom
-
Khoo Teck Puat HospitalCompletedObstructive Sleep ApneaSingapore
-
Sheng ZhangRecruitingAdvanced Solid Tumors | Chemotherapy-Induced Peripheral Neuropathy | Urothelial Carcinoma | Antibody-drug ConjugatesChina
-
Herlev and Gentofte HospitalCompleted
-
Qassim UniversityCompletedChronic Venous InsufficiencySaudi Arabia
-
University of HaifaCompletedHealthy Runners. Compression Stocking and PerformanceIsrael
-
Sir Mortimer B. Davis - Jewish General HospitalCanadian Institutes of Health Research (CIHR); Sigvaris CorporationCompletedDeep Venous ThrombosisUnited States, Canada
-
Pirogov Russian National Research Medical UniversityActive, not recruitingVaricose Veins Leg | Chronic Venous DisorderRussia
-
Naestved HospitalCompleted